On April 10, 2025 3B Pharmaceuticals GmbH (3BP), a leader in the development of targeted radiopharmaceuticals, and TetraKit Technologies (TT), developing cuttingedge click chemistry radiolabeling technologies, reported a strategic collaboration in the targeted radiotherapy field (Press release, 3B Pharmaceuticals, APR 10, 2025, View Source [SID1234651866]). This partnership will leverage the unique strengths of both companies towards development of a drug candidate, which can be labeled with astatine-211, a highly promising alpha particle-emitting radionuclide to treat cancer patients.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

This collaboration has the potential to advance an emerging class of peptide radiopharmaceuticals labeled with astatine-211. "We are very excited to work with 3BP," said Andreas Jensen, CEO of TetraKit Technologies. "By combining our radiolabeling platform with the impressive drug discovery know-how and expertise of a highly reputable and established company such as 3BP, we are confident that we can advance the development of a ground-breaking novel drug that harnesses the promising properties of astatine-211 and sets the stage for further advances in the field."